CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today the extension of the antibody library collaboration with ImClone Systems Incorporated (NASDAQ: IMCL) for the discovery of therapeutic antibodies. Under the terms of this agreement, ImClone will continue to have access to Dyax’s proprietary phage display technology for an additional four years.
